Annual report pursuant to Section 13 and 15(d)

Equity Instruments (Narrative) (Details)

Equity Instruments (Narrative) (Details) - USD ($)	1 Months Ended											3 Months Ended	12 Months Ended
Equity Instruments (Narrative) (Details) - USD ($)	Oct. 31, 2015	Sep. 30, 2015	Jul. 31, 2015	Jul. 30, 2015	Nov. 30, 2014	Jul. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Apr. 30, 2013	Mar. 31, 2013	Feb. 28, 2013	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 11, 2015	Mar. 31, 2014
Class Of Stock [Line Items]
Issued stock in connection with public offerings, net of costs, shares							10,563,381		2,100,000		1,542,389
Shares issued price per share							$ 2.84		$ 2.43		$ 3.10
Proceeds from issuance of common stock net of issuance costs							$ 28,800,000		$ 4,800,000		$ 4,500,000
Proceeds from issuance of common stock							30,000,000						$ 65,975	$ 87,984	$ 41,303,750
Exercise price of warrant issued, dollars per share													$ 0.38
Warrants, expiration date													Sep. 24, 2016
Placement agent fees							$ 999,000
Placement agent fees as a percentage of gross proceeds							3.30%
Warrants outstanding													11,677,700
Warrants, weighted average exercise price													$ 0.38
Shares conversion, number of common stock equivalent to each preferred stock								3,270
Repayments of notes payable			$ 333,333			$ 666,666							$ 30,333,333	$ 25,000,000	$ 5,982,155
Extension of warrant expiration date													$ (149,615)
Common stock reserved for future issuance													24,365,285
Series B Preferred Stock [Member]
Class Of Stock [Line Items]
Conversion of Series B preferred stock to common stock, shares								2,364.9							2,364.9
Platinum Montaur Life Sciences Llc [Member]
Class Of Stock [Line Items]
Repayments of notes payable								$ 4,781,333							$ 4,800,000
Common Stock [Member]
Class Of Stock [Line Items]
Issued stock in connection with public offerings, net of costs, shares															14,205,770
Issued stock upon exercise of warrants, net, shares					3,843,223								4,977,679	3,843,223	3,000,000
Shares conversion, number of common stock equivalent to each preferred stock								3,270
Common Stock [Member] \| Series B Preferred Stock [Member]
Class Of Stock [Line Items]
Conversion of Series B preferred stock to common stock, shares														9,960,420	5,682,933
Common Stock [Member] \| Macrophage Therapeutics [Member]
Class Of Stock [Line Items]
Warrants, number of securities called by warrants													300			300
Exercise price of warrant issued, dollars per share													$ 2,000
Minimum [Member]
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share													0.01
Maximum [Member]
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share													3.04
Series JJ Warrants [Member]
Class Of Stock [Line Items]
Warrants, number of securities called by warrants							3,169,015
Exercise price of warrant issued, dollars per share							$ 3.83
Reclassification to additional paid in capital					$ 7,700,000
Series X Warrants [Member] \| Platinum Montaur Life Sciences Llc [Member]
Class Of Stock [Line Items]
Warrants exercised										3,000,000
Issued stock upon exercise of warrants, net, shares										3,000,000
Proceeds from warrant exercises										$ 1,380,000
Series X Warrants And Series AA Warrants [Member] \| Platinum Montaur Life Sciences Llc [Member]
Class Of Stock [Line Items]
Number of common shares underlying Series B Preferred Stock								7,733,223
Series HH Warrants [Member]
Class Of Stock [Line Items]
Warrants, number of securities called by warrants								301,205
Exercise price of warrant issued, dollars per share													$ 2.49
Warrants, expiration date													Jun. 25, 2023
Warrants outstanding													301,205
Series HH Warrants [Member] \| General Electric Capital Corporation/MidCap Financial SBIC, LP [Member]
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share								$ 2.49
Series II Warrants [Member]
Class Of Stock [Line Items]
Warrants, number of securities called by warrants								275,000
Exercise price of warrant issued, dollars per share													$ 3.04
Warrants, expiration date													Jun. 25, 2018
Warrants outstanding													275,000
Class of warrant term								5 years
Series II Warrants [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share								$ 3.04
Series KK warrants [Member}
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share													$ 1.918
Warrants, expiration date													Mar. 04, 2021
Warrants outstanding													391,032
Series KK warrants [Member} \| Oxford Finance, LLC [Member]
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share																	$ 1.918
Warrants outstanding																	391,032
Series BB [Member]
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share													$ 2.00
Warrants, expiration date													Jul. 07, 2018
Warrants outstanding													300,000
Warrant, outstanding extended term				3 years
Warrant, outstanding extended term, month and year				2018-07
Extension of warrant expiration date												$ 150,000
Series LL Warrants [Member]
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share													$ 0.01
Warrants, expiration date													Aug. 31, 2035
Warrants outstanding													9,777,130
Warrants exercised	5,000,000
Issued stock upon exercise of warrants, net, shares	4,977,679
Series MM warrants [Member] \| Chardan Capital Markets, LLC [Member]
Class Of Stock [Line Items]
Exercise price of warrant issued, dollars per share	$ 2.50	$ 2.50										$ 2.50
Number of warrants issued to purchase common stock		150,000
Common Stock Warrants Issuable	150,000
Issued warrants in connection with advisory services agreement												$ 256,000
Warrant, Outstanding Term	4 years	4 years